Bayer AG has entered a substantial global licensing and collaboration agreement with Kumquat Biosciences to develop and commercialize a KRAS G12D inhibitor, a promising targeted therapy for prevalent cancer mutations. The collaboration, valued at up to $1.3 billion including milestones and royalties, underscores Bayer's commitment to advancing its early precision oncology portfolio, especially in pancreatic, colorectal, and lung cancers. This deal follows recent FDA clearance of the IND application, with Kumquat initiating early-phase studies before Bayer assumes further development and commercialization. The KRAS G12D mutation, notably prevalent in aggressive cancers, has remained an elusive target, making this partnership a significant milestone in precision medicine.